ArticleEuropean journal of human genetics : EJHG2012
Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders.
Article in European journal of human genetics : EJHG, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Mapping diagnostic practices in hemoglobinopathies: a cross-country HELIOS COST Action study.Blood advances · 2026Article
- Expanding the Australian Newborn Blood Spot Screening Program using genomic sequencing: do we want it and are we ready?European journal of human genetics : EJHG · 2023Article
- Primary care provider perspectives on using genomic sequencing in the care of healthy children.European journal of human genetics : EJHG · 2020Article
- Sickle cell carriers' unmet information needs: Beyond knowing trait status.Journal of genetic counseling · 2019Article
- Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: A Short Review on Classical Laboratory Methods-Isoelectric Focusing, HPLC, and Capillary Electrophoresis.International journal of neonatal screening · 2018Review
- A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents.American journal of human genetics · 2015Review
- Genetics professionals' opinions of whole-genome sequencing in the newborn period.Journal of genetic counseling · 2015Article
- Disparities in current and future childhood and newborn carrier identification.Journal of genetic counseling · 2014Article
- Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics.Human mutation · 2013Review
- Newborn screening for sickle cell disease: whose reproductive benefit?European journal of human genetics : EJHG · 2012Article
- Reply to Ross' commentary: Reproductive benefit through newborn screening: preferences, policy and ethics.European journal of human genetics : EJHG · 2012Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Newborn screening (NBS) programs aim to identify affected infants before the onset of treatable disorders. Historically, benefits to the family and society were considered secondary to this clinical benefit; yet, recent discourse defending expanded NBS has argued that screening can in part be justified by secondary benefits, such as learning reproductive risk information to support family planning ('reproductive benefit'). Despite increased attention to these secondary benefits of NBS, stakeholders' values remain unknown. We report a mixed methods study that included an examination of providers' views toward the pursuit of reproductive risk information through NBS, using sickle cell disorder carrier status as an example. We surveyed a stratified random sample of 1615 providers in Ontario, and interviewed 42 providers across 7 disciplines. A majority endorsed the identification of reproductive risks as a goal of NBS (74-77%). Providers' dominant rationale was that knowledge of carrier status is an important and inherent benefit of NBS as it allows people to make reproductive choices, which is consistent with the goals of disease prevention. However, some challenged its appropriateness, questioning its logic, timing and impact on disease prevention. Others were sensitive to intruding on individuals' choices or children's independent rights. While the dominant view is consistent with discourse defending expanded NBS, it deviates from the traditional screening principles that underpin most public health interventions. Broader discussion of the balance between benefits to screened individuals and those to families and societies, in the context of public health programs, is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.